Characteristics Number of reports, no. (%) Number of reports, no. (%) Number of reports, no. (%) Number of reports, no. (%)
Sorafenib Lenvatinib Regorafenib Cabozantinib
Country
United States 271(13.6) 80(25.2) 237(37.6) 1211(68.6)
Japan 191(9.6) 38(11.9) 122(19.4) 113(6.4)
France 46(2.3) 14(4.4) 47(7.5) 79(4.5)
others 410(20.6) 165(51.9) 203(32.2) 277(15.7)
Unknown or missing 1076(54.0) 21(6.6) 21(3.3) 86(4.9)
Reporter
Medical staff 1524(76.4) 309(97.2) 502(79.7) 663(37.5)
Non-medical staff 314(15.7) 6(1.9) 128(20.3) 1072(60.7)
Unknown or missing 156(7.8) 3(0.9) / 31(1.8)
Reporting time
2006 136(6.8) / / /
2007 83(4.2) / / /
2008 105(5.3) / / /
2009 177(8.9) / / /
2010 221(11.1) / / /
2011 224(11.2) / / /
2012 145(7.3) / 4(0.6) /
2013 116(5.8) / 54(8.6) 55(3.1)
2014 124(6.2) / 92(14.6) 46(2.6)
2015 109(5.5) 10(3.1) 73(11.6) 50(2.8)
2016 109(5.5) 12(3.8) 66(10.5) 45(2.5)
2017 100(5.0) 17(5.3) 100(15.9) 160(9.1)
2018 134(6.7) 18(5.7) 87(13.8) 264(14.9)
2019 96(4.8) 66(20.8) 60(9.5) 346(19.6)
2020 61(3.1) 85(26.7) 75(11.9) 345(19.5)
2021 54(2.7) 110(34.6) 19(3.0) 455(25.8)
Gender
Female 520(26.1) 163(51.3) 254(40.3) 508(28.8)
Male 1394(69.9) 155(48.7) 358(56.8) 1208(68.4)
Unknown or missing 80(4.0) / 18(2.9) 50(2.8)
Age (year)
< 18 21(1.1) 8(2.5) 2(0.3) 7(0.4)
18-64 727(36.5) 127(39.9) 249(39.5) 478(27.1)
≥65 1049(52.6) 177(55.7) 288(45.7) 597(33.8)
Unknown or missing 197(9.9) 6(1.9) 91(14.4) 684(38.7)
Cardiac AEs, Cardiac adverse events; FAERS, Food and Drug Administration’s Adverse Event Reporting System; TKI, Ttyrosine kinases inhibitors. Cardiac AEs, Cardiac adverse events; FAERS, Food and Drug Administration’s Adverse Event Reporting System; TKI, Ttyrosine kinases inhibitors. Cardiac AEs, Cardiac adverse events; FAERS, Food and Drug Administration’s Adverse Event Reporting System; TKI, Ttyrosine kinases inhibitors. Cardiac AEs, Cardiac adverse events; FAERS, Food and Drug Administration’s Adverse Event Reporting System; TKI, Ttyrosine kinases inhibitors. Cardiac AEs, Cardiac adverse events; FAERS, Food and Drug Administration’s Adverse Event Reporting System; TKI, Ttyrosine kinases inhibitors.